Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | PRCP | P42785 | 2/20 | 0.47 |
| ▸ | USP19 | O94966 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | YAP1 | P46937 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14312346 | 0.86 | MAPT (0.47) | MAPTPRCPUSP19RAB9AGFER | |
| SCHEMBL13593913 | 0.81 | ELOVL1 (0.58) | MAPTRAB9AMEN1ALDH1A1KMT2A | |
| SCHEMBL2703428 | 0.78 | GFER (0.58) | USP19GFEREPHX2NAAAOPRM1 | |
| SCHEMBL2471516 | 0.77 | OPRL1 (0.56) | GFEREPHX2NAAAOPRM1OPRD1 | |
| SCHEMBL2467799 | 0.76 | OPRL1 (0.57) | GFEREPHX2OPRM1TACR1ALDH1A1 | |
| SCHEMBL2467659 | 0.76 | OPRL1 (0.57) | GFEREPHX2OPRM1TACR1ALDH1A1 | |
| SCHEMBL2517917 | 0.75 | OPRL1 (0.54) | GFEREPHX2OPRM1OPRD1TACR1 | |
| SCHEMBL2468618 | 0.75 | CHRM5 (0.54) | GFEREPHX2MEN1KMT2A | |
| SCHEMBL2517627 | 0.75 | CHRM5 (0.54) | GFEREPHX2MEN1ALDH1A1KMT2A | |
| SCHEMBL2472907 | 0.75 | GFER (0.46) | USP19GFEREPHX2NAAATACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371366-A1 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-2228065-A2 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNH2, KCNQ5 | MAPT 3715/4885PRCP 4711/4885USP19 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.